DOCSLIB.ORG

Controlled Drug Schedules, Violations & Penalties

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Controlled Drug Schedules, Violations & Penalties CONTROLLED DRUG SCHEDULES, VIOLATIONS & PENALTIES A REFERENCE FOR THE LAW ENFORCEMENT COMMUNITY April 2015 Prepared by the DEPARTMENT OF CONSUMER PROTECTION Drug Control Division TABLE OF CONTENTS SECTION I CONTROLLED DRUG SCHEDULES & VIOLATIONS An alphabetical listing of controlled drugs by their brand, generic and/or street name that includes each drug’s schedule and the violation(s) from the Connecticut General Statutes (CGS) that are associated with each drug’s sale and/or possession. SECTION II CONTROLLED DRUG VIOLATIONS & PENALTIES A numerical listing of controlled drug violations by their section number in the Connecticut General Statutes (CGS) and the penalty(ies) associated with each violation. SECTION III SUMMARY OF FEDERAL METHAMPHETAMINE STATUTES 2 S E C T I O N I CONTROLLED DRUG SCHEDULES & VIOLATIONS The ‘Schedules of Controlled Substances’ may be found in Sections 21a-243-7 through 21a-243-11, inclusive, of the Regulations of Connecticut State Agencies. www.ct.gov/dcp/lib/dcp/dcp_regulations/21a-243_designation_of_controlled_drugs.pdf 3 Drug State CS Drug Type AKA Sale or Quantity Person Drug- CGS Schedule Possession? Dependent or Not Violation APAP = Acetaminophen APAP = Acetaminophen Drug-Dependent ? ASA = Aspirin ASA = Aspirin “2C-C” Designer Drug - Stimulant “Bath Salts” Federal CS Schedule 1 “2C-D” Designer Drug - Stimulant “Bath Salts” Federal CS Schedule 1 “2C-E” Designer Drug - Stimulant “Bath Salts” Federal CS Schedule 1 “2C-H” Designer Drug - Stimulant “Bath Salts” Federal CS Schedule 1 “2C-I” Designer Drug - Stimulant “Bath Salts” Federal CS Schedule 1 “2C-N” Designer Drug - Stimulant “Bath Salts” Federal CS Schedule 1 “2C-P” Designer Drug - Stimulant “Bath Salts” Federal CS Schedule 1 “2C-T-2” Designer Drug - Stimulant “Bath Salts” Federal CS Schedule 1 “2C-T-4” Designer Drug - Stimulant “Bath Salts” Federal CS Schedule 1 Acetone Restricted Volatile Substance Sale Any Quantity Either 21a-245 Possession Any Quantity Either 21a-245 4 Acetyldihydrocodeine 1 Narcotic Sale Any Quantity Either 21a-277(a) Sale Any Quantity Not Drug Dependent 21a-278(b) Possession Any Quantity Either 21a-279(a) Adderall® 2 Stimulant Mixed Amphetamines Sale Any Quantity Either 21a-277(b) Sale Any Quantity Not Drug Dependent 21a-278(b) Possession Any Quantity Either 21a-279(c) Adipex-P® 4 Stimulant Phentermine Sale Any Quantity Either 21a-277(b) Possession Any Quantity Either 21a-279(c) 1 “AKB48” Designer Drug – Hallucinogen Cannabimimetic Agents; Synthetic Sale Any Quantity Either 21a-277(a) Charges valid only if the Cannabis substance has a psychotropic response Sale Any Quantity Not Drug Dependent 21a-278(b) primarily by agonist activity at cannabinoid- specific receptors affecting Possession Any Quantity Either 21a-279(b) the CNS. Alfenta® 2 Narcotic Alfentanil Sale Any Quantity Either 21a-277(a) Sale Any Quantity Not Drug Dependent 21a-278(b) Possession Any Quantity Either 21a-279(a) Alfentanil 2 Narcotic Alfenta® Sale Any Quantity Either 21a-277(a) Sale Any Quantity Not Drug Dependent 21a-278(b) Possession Any Quantity Either 21a-279(a) Alphamethylfentanyl 1 Designer Drug - Depressant “China White” Sale Any Quantity Either 21a-277(a) Sale Any Quantity Not Drug Dependent 21a-278(b) Possession Any Quantity Either 21a-279(a) 5 Alprazolam 4 Depressant Xanax® Sale Any Quantity Either 21a-277(b) Possession Any Quantity Either 21a-279(c) Alurate® 3 Depressant Aprobarbital Sale Any Quantity Either 21a-277(b) Possession Any Quantity Either 21a-279(c) “AM678” 1 Designer Drug – Hallucinogen Cannabimimetic Agents; Synthetic Sale Any Quantity Either 21a-277(a) Charges valid only if the Cannabis substance has a psychotropic response Sale Any Quantity Not Drug Dependent 21a-278(b) primarily by agonist activity at cannabinoid- specific receptors affecting Possession Any Quantity Either 21a-279(b) the CNS. “AM694” 1 Designer Drug – Hallucinogen Cannabimimetic Agents; Synthetic Sale Any Quantity Either 21a-277(a) Charges valid only if the Cannabis substance has a psychotropic response Sale Any Quantity Not Drug Dependent 21a-278(b) primarily by agonist activity at cannabinoid- specific receptors affecting Possession Any Quantity Either 21a-279(b) the CNS. “AM2201” 1 Designer Drug – Hallucinogen Cannabimimetic Agents; Synthetic Sale Any Quantity Either 21a-277(a) Charges valid only if the Cannabis substance has a psychotropic response Sale Any Quantity Not Drug Dependent 21a-278(b) primarily by agonist activity at cannabinoid- specific receptors affecting Possession Any Quantity Either 21a-279(b) the CNS. Ambien® 4 Depressant Zolpidem Sale Any Quantity Either 21a-277(b) Possession Any Quantity Either 21a-279(c) 6 Amobarbital 2 Depressant Amytal® Sale Any Quantity Either 21a-277(b) Possession Any Quantity Either 21a-279(c) Amphetamine 2 Stimulant Benzedrine® , “Speed” Sale Any Quantity Either 21a-277(b) Sale Any Quantity Not Drug Dependent 21a-278(b) Possession Any Quantity Either 21a-279(c) Amyl Nitrite Restricted Depressant “Poppers” , “Rush” Sale Any Quantity Either 21a-245 Possession Any Quantity Either 21a-245 Amytal® 2 Depressant Amobarbital Sale Any Quantity Either 21a-277(b) Possession Any Quantity Either 21a-279(c) Anabolic Steroids 3 Anabolic Steroid “Juice” Sale Any Quantity Either 21a-277(b) Possession Any Quantity Either 21a-279(c) Anadrol® 3 Anabolic Steroid Oxymetholone Sale Any Quantity Either 21a-277(b) Possession Any Quantity Either 21a-279(c) Anavar® 3 Anabolic Steroid Oxandrolone Sale Any Quantity Either 21a-277(b) Possession Any Quantity Either 21a-279(c) Android® 3 Anabolic Steroid Methyltestosterone Sale Any Quantity Either 21a-277(b) Possession Any Quantity Either 21a-279(c) Anexsia® 2 Narcotic Hydrocodone/APAP Sale Any Quantity Either 21a-277(a) Sale Any Quantity Not Drug Dependent 21a-278(b) Possession Any Quantity Either 21a-279(a) 7 “Angel Dust” 2 Hallucinogen “PCP”, Phencyclidine Sale Any Quantity Either 21a-277(a) Sale Any Quantity Not Drug Dependent 21a-278(b) Possession Any Quantity Either 21a-279(b) APAP with Codeine 3 Narcotic Tylenol w/ Codeine® Sale Any Quantity Either 21a-277(a) Sale Any Quantity Not Drug Dependent 21a-278(b) Possession Any Quantity Either 21a-279(a) Aprobarbital 3 Depressant Alurate® Sale Any Quantity Either 21a-277(b) Possession Any Quantity Either 21a-279(c) ASA with Codeine 3 Narcotic Empirin w/ Codeine® Sale Any Quantity Either 21a-277(a) Sale Any Quantity Not Drug Dependent 21a-278(b) Possession Any Quantity Either 21a-279(a) Ativan® 4 Depressant Lorazepam Sale Any Quantity Either 21a-277(b) Possession Any Quantity Either 21a-279(c) Barbital 4 Depressant Veronal® Sale Any Quantity Either 21a-277(b) Possession Any Quantity Either 21a-279(c) “Bath Salts” 1 Designer Drug - Stimulant “MDPV”, Mephedrone, Methylone, Sale Any Quantity Either 21a-277(b) Methylenedioxypyrovalerone Possession Any Quantity Either 21a-279(c) “BD” Restricted Volatile Substance Butanediol Sale Any Quantity Either 21a-245 Possession Any Quantity Either 21a-245 Benzedrine® 2 Stimulant Amphetamine, “Speed” Sale Any Quantity Either 21a-277(b) Sale Any Quantity Not Drug Dependent 21a-278(b) 8 Benzedrine® 2 Stimulant Amphetamine, “Speed” Possession Any Quantity Either 21a-279(c) Benzene Restricted Volatile Substance Sale Any Quantity Either 21a-245 Possession Any Quantity Either 21a-245 Benzphetamine 3 Stimulant Didrex® Sale Any Quantity Either 21a-277(b) Sale Any Quantity Not Drug Dependent 21a-278(b) Possession Any Quantity Either 21a-279(c) Beta-hydroxyfentanyl 1 Designer Drug - Narcotic Sale Any Quantity Either 21a-277(a) Sale Any Quantity Not Drug Dependent 21a-278(b) Possession Any Quantity Either 21a-279(a) Biphetamine® 2 Stimulant “Black Beauty” Sale Any Quantity Either 21a-277(b) Sale Any Quantity Not Drug Dependent 21a-278(b) Possession Any Quantity Either 21a-279(c) “Black Beauty” 2 Stimulant Biphetamine® Sale Any Quantity Either 21a-277(b) Sale Any Quantity Not Drug Dependent 21a-278(b) Possession Any Quantity Either 21a-279(c) Buprenorphine 3 Narcotic Subutex® Sale Any Quantity Either 21a-277(a) Sale Any Quantity Not Drug Dependent 21a-278(b) Possession Any Quantity Either 21a-279(a) Buprenorphine/Naloxone 3 Narcotic Suboxone® Sale Any Quantity Either 21a-277(a) Sale Any Quantity Not Drug Dependent 21a-278(b) Possession Any Quantity Either 21a-279(a) 9 Butabarbital 3 Depressant Butisol® Sale Any Quantity Either 21a-277(b) Possession Any Quantity Either 21a-279(c) Butalbital/ASA/Caffeine 3 Depressant Fiorinal® Sale Any Quantity Either 21a-277(b) Possession Any Quantity Either 21a-279(c) Butanediol Restricted Volatile Substance “BD” Sale Any Quantity Either 21a-245 Possession Any Quantity Either 21a-245 Butisol® 3 Depressant Butabarbital Sale Any Quantity Either 21a-277(b) Possession Any Quantity Either 21a-279(c) Butorphanol 4 Depressant Stadol® Sale Any Quantity Either 21a-277(b) Possession Any Quantity Either 21a-279(c) “Button” 1 Hallucinogen “Cactus”, Peyote Sale Any Quantity Either 21a-277(a) Sale Any Quantity Not Drug Dependent 21a-278(b) Possession Any Quantity Either 21a-279(b) Butyl alcohol Restricted Volatile Substance Sale Any Quantity Either 21a-245 Possession Any Quantity Either 21a-245 Butyl nitrate Restricted Volatile Substance Sale Any Quantity Either 21a-245 Possession Any Quantity Either 21a-245 “Cactus” 1 Hallucinogen “Button”, Peyote Sale Any Quantity Either 21a-277(a) Sale Any Quantity Not Drug Dependent 21a-278(b) Possession Any Quantity Either 21a-279(b) 10 “Cannabicyclohexanol 1 Designer Drug – Hallucinogen Cannabimimetic Agents, Synthetic Sale Any Quantity Either 21a-277(a)
Load more

Recommended publications
  • 4/23/2015 1 •Psychedelics Or Hallucinogens
    4/23/2015 Hallucinogens •Psychedelics or This “classic” hallucinogen column The 2 groups below are quite different produce similar effects From the classic hallucinogens Hallucinogens Drugs Stimulating 5HT Receptors Drugs BLOCKING ACH Receptors • aka “psychotomimetics” LSD Nightshade(Datura) Psilocybin Mushrooms Jimsonweed Morning Glory Seeds Atropine Dimethyltryptamine Scopolamine What do the very mixed group of hallucinogens found around the world share in common? •Drugs Resembling NE Drugs BLOCKING Glutamate Receptors •Peyote cactus Phencyclidine (PCP) •Mescaline Ketamine All contain something that resembles a •Methylated amphetamines like MDMA High dose dextromethorphan •Nutmeg neurotransmitter •New synthetic variations (“bath salts”) •5HT-Like Hallucinogens •LSD History • Serotonin • created by Albert Hofmann for Sandoz Pharmaceuticals LSD • was studying vasoconstriction produced by ergot alkaloids LSD • initial exposure was accidental absorption thru skin • so potent ED is in millionths of a gram (25-250 micrograms) & must be delivered on something else (sugar cube, gelatin square, paper) Psilocybin Activate 5HT2 receptors , especially in prefrontal cortex and limbic areas, but is not readily metabolized •Characteristics of LSD & Other “Typical” •Common Effects Hallucinogens • Sensory distortions (color, size, shape, movement), • Autonomic (mostly sympathetic) changes occur first constantly changing (relatively mild) • Vivid closed eye imagery • Sensory/perceptual changes follow • Synesthesia (crossing of senses – e.g. hearing music
    [Show full text]
  • Methylphenidate Hydrochloride
    Application for Inclusion to the 22nd Expert Committee on the Selection and Use of Essential Medicines: METHYLPHENIDATE HYDROCHLORIDE December 7, 2018 Submitted by: Patricia Moscibrodzki, M.P.H., and Craig L. Katz, M.D. The Icahn School of Medicine at Mount Sinai Graduate Program in Public Health New York NY, United States Contact: [email protected] TABLE OF CONTENTS Page 3 Summary Statement Page 4 Focal Point Person in WHO Page 5 Name of Organizations Consulted Page 6 International Nonproprietary Name Page 7 Formulations Proposed for Inclusion Page 8 International Availability Page 10 Listing Requested Page 11 Public Health Relevance Page 13 Treatment Details Page 19 Comparative Effectiveness Page 29 Comparative Safety Page 41 Comparative Cost and Cost-Effectiveness Page 45 Regulatory Status Page 48 Pharmacoepial Standards Page 49 Text for the WHO Model Formulary Page 52 References Page 61 Appendix – Letters of Support 2 1. Summary Statement of the Proposal for Inclusion of Methylphenidate Methylphenidate (MPH), a central nervous system (CNS) stimulant, of the phenethylamine class, is proposed for inclusion in the WHO Model List of Essential Medications (EML) & the Model List of Essential Medications for Children (EMLc) for treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) under ICD-11, 6C9Z mental, behavioral or neurodevelopmental disorder, disruptive behavior or dissocial disorders. To date, the list of essential medications does not include stimulants, which play a critical role in the treatment of psychotic disorders. Methylphenidate is proposed for inclusion on the complimentary list for both children and adults. This application provides a systematic review of the use, efficacy, safety, availability, and cost-effectiveness of methylphenidate compared with other stimulant (first-line) and non-stimulant (second-line) medications.
    [Show full text]
  • Protabase Record Display Datura Stramonium L
    Protabase Record display www.prota.org Datura stramonium L. Protologue Sp. pl. 1: 179 (1753). Family Solanaceae Chromosome number 2n = 24 Vernacular names Thorn apple, green thorn apple, Jimson weed, Jamestown weed, devil’s apple, devil’s trumpet, stramonium (En). Pomme épineuse, stramoine, datura, feuille du diable, herbe du diable (Fr). Figueira do inferno, pomo espinhoso, erva dos bruxos, palha verde, estramonio (Po). Muranha (Sw). Origin and geographic distribution Datura stramonium is native to the Americas and has been introduced in many tropical, subtropical and even temperate regions. It is a naturalized weed in many African countries, but is probably seriously under-reported. Uses Datura stramonium and Datura metel L. have largely similar medicinal uses throughout the world. The most widely known use of Datura stramonium and of other Datura species is for relieving asthma, cough, tuberculosis and bronchitis by smoking the dried leaves, roots or flowers. ‘Asthma cigarettes’ have been shown to be very effective in some cases, but in other cases they had little or no effect. Cigarettes made with the leaves are also used to treat Parkinson’s disease. A decoction or infusion of leaves is given as a sedative to mental and schizophrenic patients. The leaves are applied as a dressing to cure rheumatic pain, swellings, wounds, gout, burns, ingrown toe-nails, fungal infections, tumours and ulcers. Dried pulverized leaves are dusted on wounds or applied after mixing the powder with fat or Vaseline. In DR Congo pounded fresh root and fresh leaves are soaked in water and the liquid is given in enema as an abortifacient.
    [Show full text]
  • The Stimulants and Hallucinogens Under Consideration: a Brief Overview of Their Chemistry and Pharmacology
    Drug and Alcohol Dependence, 17 (1986) 107-118 107 Elsevier Scientific Publishers Ireland Ltd. THE STIMULANTS AND HALLUCINOGENS UNDER CONSIDERATION: A BRIEF OVERVIEW OF THEIR CHEMISTRY AND PHARMACOLOGY LOUIS S. HARRIS Dcparlmcnl of Pharmacology, Medical College of Virginia, Virginia Commonwealth Unwersity, Richmond, VA 23298 (U.S.A.) SUMMARY The substances under review are a heterogenous set of compounds from a pharmacological point of view, though many have a common phenylethyl- amine structure. Variations in structure lead to marked changes in potency and characteristic action. The introductory material presented here is meant to provide a set of chemical and pharmacological highlights of the 28 substances under con- sideration. The most commonly used names or INN names, Chemical Abstract (CA) names and numbers, and elemental formulae are provided in the accompanying figures. This provides both some basic information on the substances and a starting point for the more detailed information that follows in the individual papers by contributors to the symposium. Key words: Stimulants, their chemistry and pharmacology - Hallucinogens, their chemistry and pharmacology INTRODUCTION Cathine (Fig. 1) is one of the active principles of khat (Catha edulis). The structure has two asymmetric centers and exists as two geometric isomers, each of which has been resolved into its optical isomers. In the plant it exists as d-nor-pseudoephedrine. It is a typical sympathomimetic amine with a strong component of amphetamine-like activity. The racemic mixture is known generically in this country and others as phenylpropanolamine (dl- norephedrine). It is widely available as an over-the-counter (OTC) anti- appetite agent and nasal decongestant.
    [Show full text]
  • Nightshade”—A Hierarchical Classification Approach to T Identification of Hallucinogenic Solanaceae Spp
    Talanta 204 (2019) 739–746 Contents lists available at ScienceDirect Talanta journal homepage: www.elsevier.com/locate/talanta Call it a “nightshade”—A hierarchical classification approach to T identification of hallucinogenic Solanaceae spp. using DART-HRMS-derived chemical signatures ∗ Samira Beyramysoltan, Nana-Hawwa Abdul-Rahman, Rabi A. Musah Department of Chemistry, State University of New York at Albany, 1400 Washington Ave, Albany, NY, 12222, USA ARTICLE INFO ABSTRACT Keywords: Plants that produce atropine and scopolamine fall under several genera within the nightshade family. Both Hierarchical classification atropine and scopolamine are used clinically, but they are also important in a forensics context because they are Psychoactive plants abused recreationally for their psychoactive properties. The accurate species attribution of these plants, which Seed species identifiction are related taxonomically, and which all contain the same characteristic biomarkers, is a challenging problem in Metabolome profiling both forensics and horticulture, as the plants are not only mind-altering, but are also important in landscaping as Direct analysis in real time-mass spectrometry ornamentals. Ambient ionization mass spectrometry in combination with a hierarchical classification workflow Chemometrics is shown to enable species identification of these plants. The hierarchical classification simplifies the classifi- cation problem to primarily consider the subset of models that account for the hierarchy taxonomy, instead of having it be based on discrimination between species using a single flat classification model. Accordingly, the seeds of 24 nightshade plant species spanning 5 genera (i.e. Atropa, Brugmansia, Datura, Hyocyamus and Mandragora), were analyzed by direct analysis in real time-high resolution mass spectrometry (DART-HRMS) with minimal sample preparation required.
    [Show full text]
  • Ketamine Psychedelic Psychotherapy
    KETAMINE PSYCHEDELIC PSYCHOTHERAPY EVGENY KRUPITSKY AND ELI KOLP INTRODUCTION Ketamine hydrochloride is a general anesthetic which has been used for noncon- ventional applications in substance abuse rehabilitation because of its psychedelic properties. This chapter summarizes the results of the research on KPP (ketamine psychedelic psychotherapy), principally with alcoholics and heroin addicts. Mechanisms underlying the effects of hallucinogen-assisted psychotherapy are addressed. Research illustrates how the temporary but effective anti-addictive benefits for a short period of time can be extended for longer periods of time to improve overall long-term adjustment and level of functioning. Ketamine hydrochloride, a prescription drug used for general anesthesia, induces profound psychedelic experiences when administered in sub-anesthetic .doses. Ketamine was originally synthesized in 1962 by the American chemist Calvin Stevens, and in 1966 Parke-Davis patented it for use as an anesthetic in humans. Ketamine became the most widely used anesthetic during the Vietnam War when American anesthesiologists and surgeons became familiar with the agent. In 1970, the U.S. Food and Drug Administration approved the use of ketamine with children, adults, and the elderly. Since that time, ketamine has been widely used in hospitals and for office procedures because of its large margin of safety, rapid onset, and short duration of action. More than 7,000 68 TREATTNG SUBSTANCE ABUSE published reports describe ketamine's high level of effectiveness and its biologi- cal safety (Shapiro et al. 1972; Reich and Silvay 1989; Ross and Fochtman 1995; Dachs and Innes 1997; Bauman et al. 1999; Ersek 2004). Clinical studies have detected no long-term impairment of behavior or personality functioning as a result of ketamine use (Siegal 1978).
    [Show full text]
  • (Antimuscarinic) Drugs?
    © July - August 2018 How well do you know your anticholinergic (antimuscarinic) drugs? nticholinergic drugs, prescribed for a variety of clini- Acal conditions, are amongst the most frequently used prescription drugs in BC (Table 1). Also referred to as “an- timuscarinics,” such drugs specifically block muscarinic receptors for acetylcholine (ACh).1 Muscarinic ACh recep- tors are important in the parasympathetic nervous system that governs heart rate, exocrine glands, smooth muscles, clude drugs whose active metabolites are potent- as well as brain function. In contrast, nicotinic ACh recep- ly antimuscarinic,5 or which often cause typical tors stimulate contraction of striated muscles. This Letter is AC adverse effects such as dry mouth or urinary intended to remind clinicians of commonly used drugs that retention.6 People taking antihistamines, antide- have anticholinergic (AC), or technically, antimuscarinic pressants, antipsychotics, opioids, antimuscarinic properties, and of their potential adverse effects. inhalers, or many other drugs need to know that Beneficial and harmful effects of anticholinergic drugs have blockade of ACh receptors can cause bothersome been known for centuries. In Homer’s Odyssey, the nymph or even dangerous adverse effects (Table 3). pharmacologist Circe utilized central effects of atropinics Subtle and not-so-subtle toxicity in the common plant jimson weed (Datura stramonium) to cause delusions in the crew of Odysseus. Believing they Students often learn the adverse effects of anticho- had been turned into pigs, they could be herded.2 linergics from a mnemonic, e.g.: “Blind as a bat, Sometimes a drug is recommended specifically for its an- mad as a hatter, red as a beet, hot as a hare, dry as ticholinergic potency.
    [Show full text]
  • 3,4-Methylenedioxymethcathinone (Methylone) [“Bath Salt,” Bk-MDMA, MDMC, MDMCAT, “Explosion,” “Ease,” “Molly”] December 2019
    Drug Enforcement Administration Diversion Control Division Drug & Chemical Evaluation Section 3,4-Methylenedioxymethcathinone (Methylone) [“Bath salt,” bk-MDMA, MDMC, MDMCAT, “Explosion,” “Ease,” “Molly”] December 2019 Introduction: discriminate DOM from saline. 3,4-Methylenedioxymethcathinone (methylone) is a Because of the structural and pharmacological similarities designer drug of the phenethylamine class. Methylone is a between methylone and MDMA, the psychoactive effects, adverse synthetic cathinone with substantial chemical, structural, and health risks, and signs of intoxication resulting from methylone pharmacological similarities to 3,4-methylenedioxymeth- abuse are likely to be similar to those of MDMA. Several chat amphetamine (MDMA, ecstasy). Animal studies indicate that rooms discussed pleasant and positive effects of methylone when methylone has MDMA-like and (+)-amphetamine-like used for recreational purpose. behavioral effects. When combined with mephedrone, a controlled schedule I substance, the combination is called User Population: “bubbles.” Other names are given in the above title. Methylone, like other synthetic cathinones, is a recreational drug that emerged on the United States’ illicit drug market in 2009. It is perceived as being a ‘legal’ alternative to drugs of Licit Uses: Methylone is not approved for medical use in the United abuse like MDMA, methamphetamine, and cocaine. Evidence States. indicates that youths and young adults are the primary users of synthetic cathinone substances which include methylone. However, older adults also have been identified as users of these Chemistry: substances. O H O N CH3 Illicit Distribution: CH O 3 Law enforcement has encountered methylone in the United States as well as in several countries including the Netherlands, Methylone United Kingdom, Japan, and Sweden.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Oregon Dur Board Newsletter a N E Vidence B Ased D Rug T Herapy R Esource  Copyright 2002 Oregon State University
    OREGON DUR BOARD NEWSLETTER A N E VIDENCE B ASED D RUG T HERAPY R ESOURCE COPYRIGHT 2002 OREGON STATE UNIVERSITY. ALL RIGHTS RESERVED Volume 4, Issue 2 Also available on the web and via e-mail list-serve at April 2002 http://pharmacy.orst.edu/drug_policy/drug_policy.html A Review of Stimulant Medications By Ann Hamer, Pharm. D., OSU College of Pharmacy Attention deficit hyperactivity disorder (ADHD) is a psychiatric disorder four hours (5,6). Measures of efficacy included behavior frequency, characterized by inattention, hyperactivity, or impulsivity that is more completion and accuracy of academic problems, independent frequent or severe than is appropriate for the patient’s developmental observations, as well as teacher and counselor ratings. The extended level(1). It is estimated that 3 to 7 % of children have ADHD making it one release property of Concerta is based on its OROS delivery system (an of the most common psychiatric disorders of childhood and osmotically active trilayer core surrounded by a semipermeable membrane adolescence(2). with an immediate-release drug overcoat)(7). PHARMACOTHERAPY Patients new to methylphenidate should start Concerta at a dose of 18mg Stimulants are considered first-line agents for the treatment of children once daily. The dose may be adjusted based on the patient’s response in (greater than six years of age) with ADHD and are the only agents increments of 18mg per week to a maximum recommended dose of approved by the Food and Drug Administration (FDA) for this purpose(3). 54mg/day. The recommended dose conversion for patients currently Stimulant medications (including methylphenidate preparations, taking methylphenidate is summarized as follows: dextroamphetamine preparations, and pemoline) have CNS and RECOMMENDED CURRENT METHYLPHENIDATE DOSE respiratory stimulant properties and weak sympathomimetic activity.
    [Show full text]
  • SENATE BILL No. 52
    As Amended by Senate Committee Session of 2017 SENATE BILL No. 52 By Committee on Public Health and Welfare 1-20 1 AN ACT concerning the uniform controlled substances act; relating to 2 substances included in schedules I, II and V; amending K.S.A. 2016 3 Supp. 65-4105, 65-4107 and 65-4113 and repealing the existing 4 sections. 5 6 Be it enacted by the Legislature of the State of Kansas: 7 Section 1. K.S.A. 2016 Supp. 65-4105 is hereby amended to read as 8 follows: 65-4105. (a) The controlled substances listed in this section are 9 included in schedule I and the number set forth opposite each drug or 10 substance is the DEA controlled substances code which has been assigned 11 to it. 12 (b) Any of the following opiates, including their isomers, esters, 13 ethers, salts, and salts of isomers, esters and ethers, unless specifically 14 excepted, whenever the existence of these isomers, esters, ethers and salts 15 is possible within the specific chemical designation: 16 (1) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)- 17 N-phenylacetamide)......................................................................9821 18 (2) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4- 19 piperidinyl]-N-phenylacetamide)..................................................9815 20 (3) Acetylmethadol.............................................................................9601 21 (4) AH-7921 (3.4-dichloro-N-[(1- 22 dimethylaminocyclohexylmethyl]benzamide)...............................9551 23 (4)(5) Allylprodine...........................................................................9602
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]